ETUDE DE LA PHARMACOCINETIQUE DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE .

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-005131-15-FR

Enrollment

Registered

2008-10-21

Start date

2008-12-19

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile episodes in neutropenic patients MedDRA version: 9.1 Level: LLT Classification code 10053223 Term: Febrile aplasia

Interventions

Trade Name: Tacocilline Pharmaceutical Form: Intravenous infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age between 3 and 18 years old febrile aplasia during more 7 days Normal Renal functions No infection of nervous system central No septic shock No Knews resistance to pipéracilline-tazobactam. Informed consent of two parents Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy to pipéracilline-tazobactam. hospitalisation for hyperthermy without aplasia Aplasia no febrile Refusal of parents Allergy to aminosids

Design outcomes

Primary

Measure	Time frame
Main Objective: Pharmacokinetic of association pipéracilline-tazobactam in continuous infusion ;Secondary Objective: Efficacity and tolerance of association pipéracilline-tazobactam in continuous infusion ;Primary end point(s): serum level of association pipéracilline-tazobactam	—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026